

# Biological networks and GWAS: comparing and combining network methods to understand the genetics of familial breast cancer susceptibility in the GENESIS study

Héctor Climente-González<sup>1,2,3,4\*</sup>, Christine Lonjou<sup>1,2,3</sup>, Fabienne Lesueur<sup>1,2,3</sup>, Dominique Stoppa-Lyonnet<sup>5,6,7†</sup>, Nadine Andrieu<sup>1,2,3</sup>, Chloé-Agathe Azencott<sup>3,1,2</sup>, GENESIS study group<sup>¶</sup>

**1** Institut Curie, PSL Research University, F-75005 Paris, France;

**2** INSERM, U900, F-75005 Paris, France;

**3** MINES ParisTech, PSL Research University, CBIO-Centre for Computational Biology, F-75006 Paris, France;

**4** RIKEN Center for Advanced Intelligence Project (AIP), Tokyo, Japan;

**5** Service de Génétique, Institut Curie, F-75005 Paris, France;

**6** INSERM, U830, F-75005 Paris, France;

**7** Université Paris Descartes.

†For the GENESIS study group

¶Membership list can be found in the Acknowledgments section.

\* [hector.climente\(at\)riken.jp](mailto:hector.climente(at)riken.jp)

## Abstract

Network approaches to disease use biological networks, which model functional relationships between the molecules in a cell, to generate hypotheses about the genetics of complex diseases. Among them, several approaches jointly consider gene scores, representing the association between each gene and the disease, and the biological context of each gene, modeled by a network. Here, we obtain gene scores from genome-wide association studies (GWAS) and study six network approaches on GENESIS, a GWAS on French women with non-BRCA familial breast cancer. We provide a critical comparison of these six methods, discussing the impact of their mathematical formulation and of their parameters. Using a biological network yields more compelling results than standard GWAS analyses. Indeed, we find significant overlaps between our solutions and the genes identified in the largest GWAS on breast cancer susceptibility. We further propose to combine these solutions into a consensus network, which brings further insights. The consensus network contains *COPS5*, a gene related to multiple hallmarks of cancer, and 14 of its neighbors. The main drawback of network methods is that they are not robust to small perturbations in their inputs. We therefore propose a stable consensus solution, formed by the most consistently selected genes in multiple subsamples of the data. In GENESIS, it is composed of 68 genes, enriched in known breast cancer susceptibility genes (*BLM*, *CASP8*, *CASP10*, *DNAJC1*, *FGFR2*, *MRPS30*, and *SLC4A7*,  $P$ -value =  $3 \times 10^{-4}$ ) and occupying more central positions in the network than most genes. The network is organized around *CUL3*, which is involved in the regulation of several genes linked to cancer progression. In conclusion, we showed how network methods help overcome the lack of statistical power of GWAS and improve their interpretation. Project-agnostic implementations of all methods are available at <https://github.com/hclimente/gwas-tools>.

## Author summary

In genome-wide association studies (GWAS), thousands of genomes are scanned to identify variants associated with a complex trait. Over the last 15 years, GWAS have advanced our understanding of the genetics of complex diseases, and in particular of hereditary cancers. Yet, they have led to an apparent paradox: the more we perform such studies, the more it seems that the entire genome is involved in every disease. The omnigenic model offers an appealing explanation: only a limited number of *core* genes are directly involved in the disease; but gene functions are deeply interrelated, and so many other genes can alter the function of the core genes. These interrelations are often modeled as networks, and multiple algorithms have been proposed to use these networks to identify the subset of core genes involved in a specific trait. In this study, we apply and compare six such network methods on GENESIS, a GWAS dataset for familial breast cancer in the French population. Combining these approaches allows us to identify potentially novel breast cancer susceptibility genes, and provides a mechanistic explanation for their role in the development of the disease. We provide ready-to-use implementations of all the examined methods.

## 1 Introduction

In human health, genome-wide association studies (GWAS) aim at quantifying how single-nucleotide polymorphisms (SNPs) predispose to complex diseases, like diabetes or some forms of cancer [1]. To that end, in a typical GWAS thousands of unrelated samples are genotyped: the cases, suffering from the disease of interest, and the controls, taken from the general population. Then, a statistical test of association (e.g. based on logistic regression) is conducted between each individual SNP and the phenotype. Those SNPs with a P-value lower than a conservative Bonferroni threshold are candidates to further studies in an independent cohort. Once the risk SNPs have been discovered, they can be used for risk assessment, and to deepen our understanding of the disease.

GWAS have successfully identified thousands of variants underlying many common diseases [2]. However, this experimental setting also presents intrinsic challenges. Some of them stem from the high dimensionality of the problem, as every GWAS to date studies more variants than samples are genotyped. This limits the statistical power of the experiment, as only variants with larger effects can be detected [3]. This is particularly problematic since the prevailing view is that most genetic architectures involve many variants with small effects [3]. Additionally, to avoid false positives, a conservative multiple test correction is applied, typically the previously mentioned Bonferroni correction. However, Bonferroni correction is overly conservative when the statistical tests are correlated, as it is the case in GWAS [4]. Another open issue is the interpretation of the results, as the functional consequences of most common variants are unknown. On top of that, recent large-sampled studies suggest that numerous loci spread all along the genome contribute to a degree to any complex trait, in accordance with the infinitesimal model [5]. The recently proposed omnigenic model [6] offers an explanation: genes are strongly inter-related and influence each other's function, which allows alterations in most genes to impact the subset of "core" genes directly involved in the disease's mechanism. Hence, a comprehensive statistical framework which includes the structure of biological data might help alleviate the aforementioned issues.

For this reason, many authors turn to network biology to handle the complex interplay of biomolecules that lead to disease [7]. As its name suggests, network biology models biology as a network, where the biomolecules under study, often genes, are nodes, and selected functional relationships are edges that link them. These relationships come from evidence that the genes jointly contribute to a biological

function; for instance, their expressions are correlated, or their products establish a protein-protein interaction. Under this view, complex diseases are not the consequence of a single altered gene, but of the interaction of multiple interdependent molecules [8]. In fact, an examination of biological networks shows that disease genes have differential properties [8,9]: they tend to occupy central positions in the network (although not the most central ones); disease genes for the same pathology tend to be connected in modules; and often they are bottlenecks that interconect modules. Therefore, studying the neighborhood of disease-associated genes is effective at identifying new ones that are involved in the same biological functions [10].

Network-based discovery methods exploit the differential properties described above to identify disease genes on GWAS data [11]. In essence, each gene is assigned a score of association with the disease, computed from the GWAS data, and biological relationships, given by a network built on prior knowledge. Then, the problem becomes finding a functionally-related set of highly-scoring genes. Multiple solutions have been proposed to this problem, often stemming from different mathematical frameworks and considerations of what the optimal solution looks like. For example, some methods restrict the problem to specific types of subnetworks. Such is the case of LEAN [12], which focuses on “star” subnetworks, i.e. instances were both a gene and its direct interactors are associated with the disease. Other algorithms, like dmGWAS [13] and heinz [14], do not impose such strong constraints, and search for subnetworks interconnecting genes with high association scores. However, they differ in their tolerance to the inclusion of low-scoring nodes, and the topology of the solution. Lastly, other methods also consider the topology of the network, favoring groups of nodes that are not only high-scoring, but also densely interconnected; such is the case of HotNet2 [15], SConES [16], and SigMod [17].

In this work, we analyze the application of these six network methods on GWAS data. They use different interpretations of the omnigenic model, and provide a representative view of the field. We worked on the GENESIS dataset [18], a study on familial breast cancer conducted in the French population. After a classical GWAS approach, we use these network methods to identify additional breast cancer susceptibility genes. Lastly, we carry out a comparison of the solutions obtained by the different methods, and aggregate them to obtain a consensus solution of predisposition to familial breast cancer.

## 2 Results

### 2.1 Conventional SNP- and gene-based analyses retrieve the *FGFR2* locus in the GENESIS dataset

We conducted association analyses in the GENESIS dataset (Section 4.1) at both SNP and gene levels (Section 4.2). Two genomic regions had a P-value lower than the Bonferroni threshold on chromosomes 10 and 16 (S2 FigA). The former overlaps with the gene *FGFR2*; the latter with *CASC16* and the protein-coding gene *TOX3*. Variants in both *FGFR2* and *TOX3* have been repeatedly associated with breast cancer susceptibility in other case-control studies [19], *BRCA1* and *BRCA2* carrier studies [20], and in hereditary breast and ovarian cancer families negative for mutations in *BRCA1* and *BRCA2* [21]. In GENESIS only *FGFR2* was significantly associated with breast cancer at the gene-level (S2 FigB).

Closer examination reveals two other regions (3p24 and 8q24) having low, albeit not genome-wide significant, P-values. Both of them have been associated to breast cancer susceptibility in the past [22,23]. We applied an L1-penalized logistic regression using all GENESIS genotypes as input, and the phenotype (cancer/healthy) as outcome

(Section 4.5.2). The algorithm selected 100 SNPs, both from all aforementioned regions and new ones (S2 FigC). Yet, it is unclear why those SNPs were selected, as emphasized by the high P-value of some of them, which further complicates the biological interpretation. Moreover, and in opposition to what would be expected under the omnigenic model, the genes to which these SNPs map to (Section 4.3.5) are not interconnected in the protein-protein interaction network (PPIN, Section 4.3.2). Moreover, the classification performance of the model is low (sensitivity = 55%, specificity = 55%, Section 4.5). Together, these issues motivate exploring network methods, which consider not only statistical association, but also the location of each gene in a PPIN to find susceptibility genes.

## 2.2 Network methods successfully identify genes associated with breast cancer

We applied six network methods to the GENESIS dataset (Section 4.3.3). As none of the networks examined by LEAN was significant (Benjamini-Hochberg [BH] correction adjusted P-value < 0.05), we obtained five solutions (Fig 1): one for each of the remaining four gene-based methods, and one for SConES GI (which works at the SNP level).

These solutions differ in many aspects, making it hard to draw joint conclusions. For starters, the overlap between the genes featured in each solution is quite small (Fig 1A). However, the methods tend to agree on the genes with the strongest signal: genes selected by more methods tended to have lower P-value of association (Fig 1B).


Another prominent difference is the solution size: the largest solution, produced by HotNet2, contains 440 genes, while heinz's contains only 4 genes. While SConES GI did not recover any protein coding gene, working with SNP networks rather than gene networks allowed it to retrieve four subnetworks in intergenic regions, and another one overlapping an RNA gene (*RNU6-420P*).

The topologies of the five solutions differ as well (Fig 1C), as measured by the median centrality and the number of connected components (Table 1). Three methods yield more than one connected component: SConES, as described above, SigMod, and HotNet2. HotNet2 produced 135 subnetworks, 115 of which have fewer than five genes. The second largest subnetwork (13 nodes) contains the two breast cancer susceptibility genes *CASP8* and *BLM* (Section 4.6).

**Table 1. Summary statistics on the solutions of multiple network methods on the PPIN. The first row contains the summary statistics on the whole PPIN.**

Network	# genes	# edges	# components	Betweenness	$\hat{P}_{\text{gene}}$	# genes in consensus
HINT HT	13 619	142 541	15	16 706	0.46	93/93
dmGWAS	194	450	1	49 115	0.19	55/93
heinz	4	3	1	113 633	0.001	4/93
HotNet2	440	374	130	7 739	0.048	63/93
LEAN	0	0	0	-	-	0/93
SConES GI	0 (1)	0	0	-	-	0/93
SigMod	142	249	11	92 603	0.008	84/93
Consensus	93	186	21	50 737	0.006	93/93
Stable consensus	68	49	32	94 854	0.005	43/93

**# genes:** number of genes selected out of those that are part of the PPIN; for SConES GI the total number of genes, including RNA genes, was added in parentheses. **# components :** number of connected components. **Betweenness:** median betweenness of the selected genes in the PPIN.  $\hat{P}_{\text{gene}}$ : median VEGAS2 P-value of the selected genes. **# genes in consensus:** number of genes in common between the method's solution, and the 93 genes in the consensus solution.



**Fig 1. Overview of the solutions produced by the different network methods (Section 4.3.3) on the GENESIS dataset.** As LEAN did not produce any significant solution (BH adjusted P-value < 0.05), it was excluded. Unless indicated otherwise, results refer to genes, except for SConES GI which are at the SNP-level. (A) Overlap between the genes selected by each of the methods, measured by Pearson correlation between indicator vectors (Sections 4.5.1 and 4.3.5). (B) Distribution of VEGAS2 P-values of the genes in the PPIN not selected by any network method (12 213), and of those selected by 1 (575), 2 (73), or 3 (20) methods. (C) Solution networks produced by the different methods. (D) Manhattan plots of SNPs/genes; in black, the method's solution. The Bonferroni threshold is indicated by a red line ( $2.54 \times 10^{-7}$  for SNPs,  $1.53 \times 10^{-6}$  for genes).

Lastly, a pathway enrichment analysis (Section 4.4) also showed similarities and differences between the solutions of the different methods. It linked different parts of

SigMod's solution to four processes (S3 Table): protein translation (including mitochondrial), mRNA splicing, protein misfolding, and keratinization (BH adjusted P-values < 0.03). Interestingly, the dmGWAS solution (S4 Table) was also related to protein misfolding (*attenuation phase*, BH adjusted P-value = 0.01). However, it additionally included submodules of proteins related to mitosis, DNA damage, and regulation of TP53 (BH adjusted P-values < 0.05), which match previously known mechanisms of breast cancer susceptibility [24]. As with SigMod, the genes in HotNet2's solution (S5 Table) were involved in mitochondrial translation (BH adjusted P-value =  $1.87 \times 10^{-4}$ ), but also in glycogen metabolism and transcription of nuclear receptors (BH adjusted P-value < 0.04).


Despite their differences, there were additional common themes. All obtained solutions had lower association P-values than the whole PPIN (median VEGAS2 P-value  $\ll 0.46$ , Table 1), despite containing genes with higher P-values as well (Fig 1D). This illustrates the trade-off between controlling for type I error and biological relevance. However, there were nuances between solutions in this regard: heinz strongly favored genes with lower P-values, while dmGWAS was less conservative (median VEGAS2 P-values 0.0012 and 0.19, respectively); SConES tended to select whole LD-blocks; and HotNet2 and SigMod were less likely to select low scoring genes.

Additionally, the solutions presented other desirable properties. First, four of them were enriched in known breast cancer susceptibility genes (dmGWAS, heinz, HotNet2, and SigMod, Fisher's exact test one-sided P-value < 0.03). Second, the genes in three solutions displayed on average a significantly higher betweenness centrality than the rest of the genes (dmGWAS, HotNet2, and SigMod, Wilcoxon rank-sum test P-value <  $1.4 \times 10^{-21}$ ). This agrees with the notion that disease genes are more central than other non-essential genes [25], an observation that holds in breast cancer (one-tailed Wilcoxon rank-sum test P-value =  $2.64 \times 10^{-5}$  when comparing the betweenness of known susceptibility genes versus the rest). Interestingly, SConES selected SNPs that are also more central than the average SNP (S1 Table), suggesting that causal SNPs are also more central than non-associated SNPs.

### 2.3 A case study: the consensus solution

Despite their shared properties, the differences between the solutions of the different methods suggested that each of them captured different aspects of cancer susceptibility. Indeed, out of the 668 genes that were selected by at least one method, only 93 were selected by at least two, 20 by three, and none by four or more. Encouragingly, the more methods selected a gene, the higher its association score to the phenotype (Fig 1B), a relationship that plateaus at 2. Hence, to leverage on their strengths and compensate their respective weaknesses, we built a consensus solution that captured the genes shared among at least two solutions (Section 4.3.3). This solution (Fig 2) contained 93 genes and exhibited the aforementioned properties of the individual solutions: enrichment in breast cancer susceptibility genes and higher betweenness centrality than the rest of the genes.

A pathway enrichment analysis of the genes in the consensus solution also showed similar pathways as the individual solutions (S6 Table). We found two involved mechanisms: *mitochondrial translation* and *attenuation phase*. The former is supported by genes like *MRPS30* (VEGAS2 P-value = 0.001), which encode a mitochondrial ribosomal protein and was also linked to breast cancer susceptibility [26]. Interestingly, increased mitochondrial translation has been found in cancer cells [27], and its inhibition proposed as a therapeutic target. With regards to the attenuation phase of heat shock response, it involved three Hsp70 chaperones: HSPA1A, HSPA1B, and HSPA1L. The genes encoding these proteins are all near each other at 6p21, in the region known as HLA. In fact, out of the 22 SNPs that map to any of these three genes,



**Fig 2. Consensus solution on GENESIS (Section 4.3.3).** (A) Manhattan plot of genes; in black, the ones in the consensus solution. The Bonferroni threshold is indicated by a red line ( $1.53 \times 10^{-6}$  for genes). (B) Consensus network. Each gene is represented by a pie chart, which shows the methods that selected it. We enlarged the two most central genes (*COPS5* and *OFD1*) and those genes that are known breast cancer susceptibility genes and/or significantly associated with breast cancer susceptibility in the BCAC dataset (Section 4.6). (C) The nodes are in the same disposition as in panel B, but every gene name is indicated. We colored in pink the names of genes that are known breast cancer susceptibility genes and/or significantly associated with breast cancer susceptibility in the BCAC dataset.

9 mapped to all of them, and 4 to two, making it hard to disentangle their effects. *HSPA1A* was the most strongly associated gene (VEGAS2 P-value =  $8.37 \times 10^{-4}$ ).

Topologically, the consensus consisted of a connected component composed of 49

183  
184  
185

genes, and multiple smaller subnetworks (Fig 2B and C). Among the latter, 19 genes were in subnetworks containing a single gene or two connected nodes, implying that they did not have a consistently altered neighborhood, but were strongly associated themselves and hence picked by at least two methods. The large connected component contained genes that are highly central in the PPIN, a property which is weakly anti-correlated with the P-value of association to the disease (Pearson correlation coefficient = -0.26, S4 Fig). This suggested that these genes were selected because they were on the shortest path between another two highly associated genes. In view of this, we hypothesize that highly central genes might contribute to the heritability through alterations of their neighborhood, consistently with the omnigenic model of disease [6]. For instance, the most central node in the consensus solution is *COPS5*, a component of the COP9 signalosome which regulates multiple signaling pathways. *COPS5* is related to multiple hallmarks of cancer and is overexpressed in multiple tumors, including breast and ovarian cancer [28]. Despite its lack of association in GENESIS or in studies conducted by the Breast Cancer Association Consortium (BCAC) [19] (VEGAS2 P-value of 0.22 and 0.14 respectively), its neighbors in the consensus solution had consistently low P-values (median VEGAS2 P-value = 0.006).

## 2.4 Network methods boost discovery

We compared the results obtained with different network methods to the European sample of BCAC, the largest GWAS to date on breast cancer (Section 4.6). Although BCAC case-control studies do not necessarily target cases with a familial history of breast cancer, this comparison is pertinent since we expect a shared genetic architecture at the gene level, at which most network methods operate. This shared genetic architecture, together with BCAC's scale (90 times more samples than GENESIS) provided a reasonable counterfactual of what we would expect if GENESIS had a larger sample size. We computed a gene association score on BCAC (Section 4.6). The solutions provided by the different network methods overlapped significantly with BCAC hits (Fisher's exact test P-value < 0.019). The gene-based methods achieved comparable precision (2%-25%) and recall (1.3-12.1%) at recovering BCAC-significant genes (S5 FigA). Interestingly, while SConES GI, at the SNP-level, achieved a similar recall (8.6%), it showed a much higher precision (47.3%).

## 2.5 Network methods share limitations

We compared the six network methods in a 5-fold subsampling setting (Section 4.5). This allowed us to measure five properties (Fig 3): size of the solution; sensitivity and specificity of an L1-penalized logistic regression classifier on the selected SNPs; stability; and computational runtime. The solution size varies greatly between the different methods (Fig 3A). Heinz produced the smallest solutions, with an average of 182 selected SNPs (Section 4.3.5). The largest solutions came from SConES GI (6 256.6 SNPs), and dmGWAS (4 255.0 SNPs). LEAN did not produce any solution in any of the subsamples. Using different combinations of parameters (Section 4.3.4), we computed how good each of the methods was at recovering the results of a conventional GWAS on BCAC (Section 4.6, Fig 3B). SConES exhibits the largest area under the curve, since, when  $\lambda = 0$  (network topology is disregarded), it is equivalent to a Bonferroni correction. Between the remaining network methods, they have similar areas under the curve, with heinz being the one with the largest area.

To determine whether the selected SNPs could be used for patient classification, we computed the performance of the classifier on *test sets* (S5 FigB). The different classifiers displayed similarly poor sensitivities and specificities, all in the 0.52 – 0.56 range. Interestingly, the classifier trained on all the SNPs had a similar performance,

despite being the only method aiming only at minimizing prediction error. Of course, although these performances were low, we did not expect to separate cases from controls well using exclusively genetic data [29].

Another desirable quality of a selection algorithm is the stability of the solution with respect to small changes in the input (Section 4.5.1). Heinz was highly stable in our benchmark, while the other methods displayed similarly low stabilities (Fig 3C).

In terms of computational runtime, the fastest method was heinz (Fig 3D), which returned a solution in a few seconds. HotNet2 was the slowest (3 days and 14 hours on average). Including the time required to compute the gene scores, however, slowed down considerably gene-based methods; on this benchmark, that step took on average 1 day and 9.33 hours. Including this first step, it therefore took 5 days on average for HotNet2 to produce a result.


## 2.6 Network topology and association scores matter, and might lead to ambiguous results

As shown above, and despite their similarities, the network methods produced remarkably different solutions. This is due to the fact that each of them models the problem differently. Importantly, understanding which assumptions they make allows to understand the results more in depth. For instance, the fact that LEAN did not return any gene implies that there is no gene such that both itself and its environment are on average strongly associated with the disease.


In the GENESIS dataset, heinz's solution is very conservative, providing a small solution with the lowest median P-value (Table 1). By repeatedly selecting this compact solution, heinz was the most stable method (Fig 3C). Its conservativeness stems from its preprocessing step, which models the gene P-values as a mixture model of a beta distribution and a uniform distribution, controlled by an FDR parameter. Due to the limited signal at the gene level in this dataset (S2 FigB), only 36 of all the genes retain a positive score after that transformation. Yet, this small solution does not provide much insight into the susceptibility mechanisms to cancer. Importantly, it ignores genes that are associated to cancer in this dataset like *FGFR2*.

On the other end of the spectrum, dmGWAS, HotNet2, and SigMod produced large solutions. dmGWAS' solution is the lowest scoring solution on average. This is due to the greedy framework it uses, which has a bias for larger solutions [30]. It considered all nodes at distance 2 of the examined subnetwork, and accepted a weakly associated gene if it was linked to another, high scoring one. This is exacerbated when the results of successive greedy searches are aggregated, leading to a large, tightly connected cluster of unassociated genes (Fig 4A). This relatively low signal-to-noise ratio combined with the large solution requires additional analyses to draw conclusions, such as enrichment analyses. In the same line, HotNet2's solution is even harder to interpret, being composed of 440 genes divided into 135 subnetworks. Lastly, SigMod misses some of the highest scoring, breast cancer susceptibility genes in the dataset, like *FGFR2* and *TOX3*.

Another peculiarity of network methods is their relationship to degree centrality. We studied random rewirings of the PPIN while preserving node centrality (Section 4.7). In this setting, network methods favored central genes, as they often connect high scoring nodes (Fig 4B). This is despite the fact that highly central genes often had no association to breast cancer susceptibility (Fig 4C). This was especially the case of SigMod (S6 Fig), which selected three highly central, unassociated genes in both the PPIN and in many of the random rewirings: *COPS5*, *CUL3* and *FN1*. As we showed in Section 2.3, and will show in 2.8, there is evidence in the literature of the contribution of the first two to breast cancer susceptibility. With regards to *FN1*, it encodes a



**Fig 3. Comparison of network-based GWAS methods on GENESIS.** Each method was run 5 times on a random subset containing 80% of the samples, and tested on the remaining samples (Section 4.5). As LEAN did not select any gene, it was excluded from all panels except **D**. **(A)** Number of SNPs selected by each method and number of SNPs in the active set found by the classifier (Section 4.5.2). Points are the average over the 5 runs; the error bars represent the standard error of the mean. A grey diagonal line with slope 1 is added for comparison, indicating the upper bound of the active set (i.e. the number of SNPs in the solution). For reference, the active set of Lasso using all the SNPs included, on average, 154 117.4 SNPs. **(B)** True positive rate and true negative rate, using significant SNPs (for SConES and  $\chi^2 + \text{Bonferroni}$ ) and genes (for the remaining methods) in BCAC (Section 4.6) as true positives, of multiple parameter combinations for different methods (Section 2.7). **(C)** Pairwise Pearson correlations of the solutions produced by different methods. A Pearson correlation of 1 means the two solutions are the same. A Pearson correlation of 0 means that there is no SNP in common between the two solutions. **(D)** Runtime of the evaluated methods, by type of network used (PPIN or SNP). For gene-based methods, inverted triangles represent the runtime of the algorithm itself, and circles the total time, which includes the algorithm themselves and the additional 119 980 seconds (1 day and 9.33 hours) that VEGAS2 took on average to compute the gene scores from SNP summary statistics.



**Fig 4. Drawbacks encountered when using network methods.** (A) DmGWAS solution, with the genes colored according to the  $-\log_{10}$  of their P-value. (B) Number of times a gene was selected by either dmGWAS, heinz, LEAN, or SigMod in 100 rewirings of the PPIN (Section 4.4) and its centrality degree. (C) Centrality degree and  $-\log_{10}$  of the VEGAS2 P-value in BCAC for each of the nodes in the PPIN. We highlighted the genes selected by each method, and the ones selected by more than one (“Consensus”). We labeled the three most central genes that were picked by any method. (D) Overlap between the solutions of SConES GS, GM or GI in the different genomic regions. SNPs that were not selected in the studied network, but were selected in another one, are displayed in background color.

fibronectin, a protein of the extracellular matrix involved in cell adhesion and migration. Overexpression of *FN1* has been observed in breast cancer [31], and it is negatively correlated with poor prognosis in other cancer types [32,33].

By virtue of using a SNP subnetwork, SConES analyzes each SNP in their functional context. It can therefore select SNPs located in genes not included in the PPIN, as well as SNPs in non-coding regions or in non-interacting genes. We compared the solution of SConES in the GI network (using PPIN information), to the one using only positional information (GS network), or positional and gene annotations (GM network). Importantly, SConES produces similar results on the GS and GM networks (S3 Fig). While the solutions on those two greatly overlap with SConES GI’s, they contain additional gene-coding segments (Fig 4C). In fact the formers’ solutions are chromosome regions related to breast cancer, like 3p24 (*SLC4A7/NEK10* [34]), 5p12 (*FGF10, MRPS30* [26]), 10q26 (*FGFR2*), and 16q12 (*TOX3*). On top of those SConES GS selects region 8q24 (*POU5F1B* [35]).

## 2.7 Different parameters produce similarly-sized solutions

We explored the parameter space of the different methods by running them under different combinations of parameters (Section 4.3.4). In agreement with their formulations (Section 4.3.3), larger values of certain parameters produce less stringent solutions (S7 FigA): for HotNet2 and heinz, this is the threshold above which genes are assigned a non-zero score; for dmGWAS, it is the *d* parameter, which controls how far neighbors could be added; for SigMod, it is *nmax*, which specifies the maximum size of the solution; and for LEAN, it is the P-value threshold to consider a solution significant. Two parameters had the opposite effect (larger is more stringent): SigMod’s *maxjump*, which sets the threshold to consider an increment in  $\lambda$  “large enough”; and SConES’s  $\eta$ , where higher values produce smaller solutions. However, two of the parameters did not have the expected effect: dmGWAS’ *r*, which controls the minimum increment in the score required to add an additional gene; and SigMod’s *maxjump*, which sets the threshold to consider an increment in  $\lambda$  “large enough”. In both cases, the size of the solution was very similar across the different values. Despite the differences in size, the size of the solutions was relatively robust to the choice of parameters (S7 FigB).


We computed the Pearson correlation between the different solutions as in Section 4.5.1 to study how the parameters affected which genes and SNPs were selected (S7 FigC). This showed that dmGWAS and SigMod are robust to certain parameters: dmGWAS’ output was mostly determined by the parameter *d*, rather than *r*; SigMod’s by *nmax*, rather than *maxjump*.

SConES presented an interesting case in terms of feature selection: most of the explored combinations of parameters led to trivial solutions (either all the SNPs, or none of them were included) (S7 FigA). To explore a more meaningful parameter space, we selected the parameters in two rounds. First, we explored the whole sample space. Then, we focused in a range of  $\eta$  and  $\lambda$  1.5 orders of magnitude above and below the best parameters, respectively. This second parameter space was more diverse, and allowed to find more interesting solutions.

## 2.8 Building a stable consensus network preserves global network properties

Most of the network methods, including the consensus, were highly unstable (Fig 3), raising questions about the reliability of the results. We built a new, *stable consensus* solution using the genes selected most often across the 30 solutions obtained by running the 6 methods on 5 different splits of the data (Section 4.5). Such a network is expected to capture the subnetworks more often found altered, and hence should be more resistant to noise. We used only genes selected in at least 7 of the solutions, which corresponded to 1% of all genes selected at least once. The resulting stability-based consensus was composed of 68 genes (Fig 5). This network shares most of the properties of the consensus: breast cancer susceptibility genes are overrepresented (P-value =  $3 \times 10^{-4}$ ), as well as genes involved in mitochondrial translation and the attenuation phase (adjusted P-values 0.001 and  $3 \times 10^{-5}$  respectively); the selected genes are more central than average (P-value =  $1.1 \times 10^{-14}$ ); and a considerable number of nodes (19) are isolated (Fig 5B and C).

Despite these similarities, the consensus and the stable consensus solutions include different genes. In the stable consensus network, the most central gene is *CUL3*, which is absent from the previous consensus solution and has a low association score in both GENESIS and BCAC (P-values of 0.04 and 0.26, respectively). This gene is a component of Cullin-RING ubiquitin ligases. Encouragingly, it impacts the protein levels of multiple genes relevant for cancer progression [36], and its overexpression was also linked to increased sensitivity to carcinogens [37].



**Fig 5. Stable consensus solution on GENESIS (Section 2.8) . (A)** Manhattan plot of genes; in black, the ones in the stable consensus solution. The Bonferroni threshold is indicated by a red line ( $1.53 \times 10^{-6}$  for genes). **(B)** Stable consensus network. Each gene is represented by a pie chart, which shows the methods that selected it. We enlarged the most central gene (*CUL3*) and those genes that are known breast cancer susceptibility genes and/or significantly associated with breast cancer susceptibility in the BCAC dataset (Section 4.6). **(C)** The nodes are in the same disposition as in panel B, but every gene name is indicated. We colored in pink the names of genes that are known breast cancer susceptibility genes and/or significantly associated with breast cancer susceptibility in the BCAC dataset.

### 3 Discussion

In recent years, the ability of GWAS to unravel the mechanisms leading to complex diseases has been called into question [6]. First, the omnigenic model proposes that gene functions are interwoven with each other in a dense co-function network. The practical consequence is that larger and larger GWAS will lead to the discovery of an uninformative wide-spread pleiotropy. Second, discovery in GWAS is hindered by a

conservative statistical framework. Network methods elegantly address these two issues by using both association scores and an interaction network to take into consideration the biological context of each of the genes and SNPs. Based on what could be considered diverse interpretations of the omnigenic model, several methods for network-guided discovery have been proposed in recent years. In this article we evaluated six of these methods (Section 4.3.3) by applying them to the GENESIS study, a GWAS dataset on familial breast cancer (Section 4.1).

DmGWAS, Heinz, HotNet2, SConES and SigMod all yielded interesting solutions, which include (but are not limited to) known breast cancer susceptibility genes (Section 2.2). In general, the selected genes and SNPs were more central than most other genes and SNPs, in accordance with the observation that disease genes are more relatively central [25]. However, very central nodes are also more likely to be connecting any given random pair of nodes, making them more likely to be selected by network methods (Section 2.6). Yet, across this article we showed that the highly central genes that were selected (*COPS5*, *CUL3* and *FN1*) could plausibly be involved in breast cancer susceptibility. Despite these similarities, the solutions obtained were notably different. At one end of the spectrum, SConES and heinz preferred highly associated solutions, which in turn were small and did not shed much light on the etiology of the disease. On the other end, SigMod and dmGWAS gravitated towards larger, less associated solutions which provided a wide overview of the biological context. While this deepened our understanding of breast cancer susceptibility and provided biological hypotheses, they required further analyses. For instance, we had to examine the centrality of the selected genes to discern the extent to which that property is driving the selection of each gene (Section 2.6). Lastly, HotNet2 produced a third kind of solution: a large constellation of many, high-scoring, small subnetworks. However, all solutions shared two drawbacks. First, they were all equally bad at discriminating cases from controls. Yet, the classification accuracy of network methods was similar to that of a classifier trained on the entire genome (Section 2.5), which suggests that cases and controls are difficult to separate in the GENESIS dataset. This may be due to limited statistical power, which reduces the ability to identify relevant SNPs; but in any event, we do not expect to be able to separate people who have or will developed cancer from others on the sole basis of their genomes, ignoring all environmental factors and chance events. Second, all methods were remarkably unstable, yielding different solutions for slightly different inputs. This might partly have been caused by the instability of the P-values themselves in low statistical power settings [38]. Hence, heinz's conservative transformation of P-values, which favored only the most extreme ones, led to improved stability. Another source of instability might have been the redundancy inherent to biological networks, since they are subject to an evolutionary pressure to avoid single points of failure [39]. Hence, biological networks will often have multiple paths connecting two high-scoring nodes.

To overcome these limitations while exploiting the strengths of the individual methods, we proposed combining them into a consensus solution. We used a straightforward strategy of including any node that was recovered by multiple methods. We thus proposed two networks (Sections 2.3 and 2.8): a consensus solution, meant to address the heterogeneity of the solutions in the full dataset, and a stable consensus solution, which in addition addressed the instability of the methods. They both included the majority of the strongly associated smaller solutions and captured genes and broader mechanisms related to cancer, thus synthetizing the mechanisms altered in breast cancer cases. Thanks to their smaller size and their network structure, they provided compelling hypotheses on genes like *COPS5* and *CUL3*, which lack genome-wide association with the disease, but are related to cancer at the expression level and interact with genes with consistently high association scores. Importantly,

while the consensus approach was as unstable as the individual network-guided methods, the stable consensus network retained the ability to provide compelling hypotheses and had better stability. This supports that instability might be caused by redundant but equivalent biological mechanisms, and hence validates the conclusions obtained on the individual solutions and the consensus.

In this work, we have compared our results to significant genes and SNPs in the BCAC study [19]. Network methods showed modest precision, but much higher recall at recovering BCAC hits (Section 2.4). While precision might be desirable when a subset of good markers is required (for instance, for diagnosis), higher recall is desirable in exploratory settings. Nonetheless, BCAC was not an ideal ground truth. First, the studied populations are not completely overlapping: BCAC focused on a pan-European cohort, while GENESIS targeted the French population specifically. Second, the study designs differed: a high proportion of breast cancer cases investigated in BCAC were sporadic (not selected according to family history), while GENESIS was a homogeneous dataset not included in BCAC and which focused on the French high-risk population attending the family cancer clinics. Despite these differences, we expected some degree of shared genetic architecture, especially at the gene level. Finally, and this is indeed the motivation for this study, GWAS are unlikely to identify all genes relevant for the disease: some might only show up in rare-variant studies; others might have too low effect sizes. Network methods account for this by including genes with low association scores but with relevant topological properties. Hence, network methods and GWAS, even well-powered, are unlikely to capture exactly the same sets of genes. This might partly excuse the low precisions displayed in Section 2.4 and the low AUC displayed in Section 2.5.

As not all PPIN databases compiled the same interactions, the choice of the PPIN determines the final output. In this work we used exclusively interactions from HINT from high-throughput experiments. This responded to concerns about adding interactions identified in targeted studies and prone to a “rich getting richer” phenomenon: popular genes have a higher proportion of their interactions described [9,40], and they might bias discovery by reducing the average shortest path length between two random nodes. On the other hand, Huang et al. [10] found that larger networks were more useful than smaller networks to identify disease genes. This would support using the largest networks in our experiments. However, when we compared the impact of using a larger PPIN containing interactions from both high-throughput experiments and the literature (Section 4.3.2), we found that for most of the methods it did not greatly change the size or the stability of the solution, the classification accuracy, or the runtime (S9 Fig). This supports using only interactions from high-throughput experiments, which produced apparently similar solutions and avoided falling into “circular reasonings”, where the best-known genes were artificially pushed into the solutions as we observed in Section 2.6.

The strength of network-based analyses comes from leveraging prior knowledge to boost discovery. In consequence, they show their shortcomings on understudied genes, especially those not in the network. Out of the 32 767 genes to which we mapped the genotyped SNPs, 60.7% (19 887) were not in the PPIN. The majority of those (14 660) are non-coding genes, mainly lncRNA, miRNA, and snRNA (S8 Fig). Yet, RNA genes like *CASC16* were associated to breast cancer (Section 2.1), reminding us of the importance of using networks beyond coding genes. In addition, even protein-coding genes linked to breast cancer susceptibility [34], like *NEK10* ( $P$ -value  $1.6 \times 10^{-5}$ , overlapping with *SLC4A7*) or *POU5F1B*, were absent from the PPIN. However, on average protein-coding genes absent from the PPIN were less associated with breast cancer susceptibility (Wilcoxon rank-sum  $P$ -value =  $2.79 \times 10^{-8}$ , median  $P$ -values of 0.43 and 0.47). This could not be due to well-known genes having more known

interactions because we only used interactions from high-throughput experiments. As disease genes tend to be more central [25], we hypothesize that it was due to interactions between central genes being more likely. It is worth noting that network methods that do not use PPIs, like SConES GS and GM, did recover SNPs in *NEK10* and *CASC16*. Moreover, both SConES GM and GI recovered intergenic regions, which might contain key regulatory elements [41] and, yet, are excluded from gene-centric approaches. This shows the potential of SNP networks, in which SNPs are linked when there is evidence of co-function, to perform network-guided GWAS even in the absence of gene-level interactions. Lastly, all the methods are heavily affected by how SNPs are mapped to genes, and other strategies (e.g. eQTLs, SNPs associated to the expression of a gene) might lead to different results.

A crucial step for the gene-based methods is the computation of the gene score. In this work we used VEGAS2 [42] due to the flexibility it offers to use user-specified gene annotations. However, it presents known problems (selection of an appropriate percentage of top SNPs, long runtimes and P-value precision limited to the number of permutations [43]), and other algorithms like PEGASUS [43], SKAT [44] or COMBAT [45] might have more statistical power.

How to handle linkage disequilibrium (LD) is often a concern among GWAS practitioners. VEGAS2 accounts for LD patterns, and hence an LD pruning step would not impact gene-based network methods, although it would speed up VEGAS2's computation time. With regards to gene-based network methods, in Section 2.3 we highlighted ambiguities that appear when genes overlap or are in LD. In fact, the presented case is paradigmatic, since all three genes are located in the HLA region, the most gene-dense region of the genome [46]. Network methods are prone to selecting such genes when they are functionally related, and hence interconnected in the PPIN. But the opposite case is also true: when genes are not functionally related (and hence disconnected in the PPIN), network methods might disregard them even if they have high association scores. With regards to SConES, fewer SNPs would lead to simpler SNP networks and, possibly, shorter runtimes. However, LD patterns also affect SConES' in other ways, since its formulation penalizes selecting a SNP and not its neighbors, via a nonzero parameter  $\eta$  in Equation 5. Due to LD, nearby SNPs' P-values are correlated; and since SNP networks are determined by positional information, nearby SNPs are likely to be linked. Hence, SConES tends to select LD-blocks formed by low P-value SNPs. This might explain why SConES produces similar results on the GS and GM networks, heavily affected by LD (Section 2.6). However, this same behavior raises the burden of proof required to select SNPs with many interactions, like those mapped to hub genes in the PPIN. For this reason, SConES GI did not select any protein coding gene. We hypothesize that this is caused by the absence of joint association of a gene and a majority of its neighbors. This is supported by the lack of results from LEAN as well. Yet, a different combination of parameters could lead to a more informative SConES' solution (e.g. a lower  $\lambda$  in Equation 5), although it is unclear how to find it. In addition, due to the design of the iCOGS array (Section 4.1), the genome of GENESIS participants has not been unbiasedly surveyed: some regions are fine-mapped — which might distort gene structure in GM and GI networks — while others are under studied — hindering the accuracy with which the GS network captures the genome structure. A stringent LD pruning might address such problems.

To produce the two consensus solutions, we faced practical challenges due to the differences in interfaces, preprocessing steps, and unexpected behaviors of the various methods. To make it easier for other to apply these methods to new datasets and aggregate their solutions, we built six `nextflow` pipelines [47] with a consistent interface and, whenever possible, parallelized computation. They are available on GitHub: <https://github.com/hclimente/gwas-tools> (Section 4.9). Importantly, we

compiled those methods that had a permissive license into a Docker image for easier use,  
which is available on Docker Hub hclimente/gwas-tools.

## 4 Materials and methods

### 4.1 GENESIS dataset, preprocessing and quality control

The GENE Sisters (GENESIS) study was designed to investigate risk factors for familial breast cancer in the French population [18]. Index cases were patients with infiltrating mammary or ductal adenocarcinoma, who had a sister with breast cancer, and who have been tested negative for *BRCA1* and *BRCA2* pathogenic variants. Controls were unaffected colleagues and/or friends of the cases, born around the year of birth of their corresponding case ( $\pm 3$  years). We focused on the 2 577 samples of European ancestry, of which 1 279 were controls and 1 298 were cases. The genotyping was performed using the iCOGS array, a custom Illumina array designed to study the genetic susceptibility to hormone-related cancers [48]. It contained 211 155 SNPs, including SNPs putatively associated with breast, ovarian, and prostate cancers, SNPs associated with survival after diagnosis, and SNPs associated to other cancer-related traits, as well as candidate functional variants in selected genes and pathways.

We discarded SNPs with a minor allele frequency lower than 0.1%, those not in Hardy–Weinberg equilibrium in controls ( $P$ -value  $< 0.001$ ), and those with genotyping data missing on more than 10% of the samples. A subset of 20 duplicated SNPs in *FGFR2* were also removed. In addition, we removed the samples with more than 10% missing genotypes. After controlling for relatedness, 17 additional samples were removed (6 for sample identity error, 6 controls related to other samples, 2 cases being related to an index case, and 3 additional controls having a high relatedness score). Lastly, based on study selection criteria, 11 other samples were removed (1 control having cancer, 4 index cases with no affected sister, 3 half-sisters, 1 sister with lobular carcinoma *in situ*, 1 with a *BRCA1* or *BRCA2* pathogenic variant detected in the family, 1 with unknown molecular diagnosis). The final dataset included 1 271 controls and 1 280 cases, genotyped over 197 083 SNPs.

We looked for population structure that could produce spurious associations. A principal component analysis revealed no visual differential population structure between cases and controls (S1 Fig). Independently, we did not find evidence of genomic inflation ( $\lambda = 1.05$ ) either, further confirming the absence of confounding population structure.

### 4.2 SNP- and gene-based GWAS

To measure association between a genotype and susceptibility to breast cancer, we performed a per-SNP 1 d.f.  $\chi^2$  allelic test using PLINK v1.90 [49]. In order to obtain significant SNPs, we performed Bonferroni correction, to keep family-wise error rate below 5%. The threshold used was  $\frac{0.05}{197083} = 2.54 \times 10^{-7}$ .

Then, we used VEGAS2 [42] to compute the gene-level association score from the  $P$ -values of the SNPs mapped to them. More specifically, we mapped SNPs to genes through their genomic coordinates: all SNPs located within the boundaries of a gene,  $\pm 50$  kb, were mapped to that gene. For each gene, we computed VEGAS2 scores using only the 10% of SNPs with lowest  $P$ -values among all those that were mapped to it. We used the 62 193 genes described in GENCODE 31 [50], although only 54 612 could be mapped to at least one SNP. Out of those, we focused exclusively on the 32 767 that had a gene symbol. Out of the 197 083 SNPs remaining after quality control, 164 037 were

mapped to at least one of these genes. We also used Bonferroni correction to obtain significant genes; in this case, the threshold of significance was  $\frac{0.05}{32767} = 1.53 \times 10^{-6}$ .

### 4.3 Network methods

#### 4.3.1 Mathematical notations

In this article, we used undirected, vertex-weighted networks, or graphs,  $G = (V, E, w)$ .  $V = \{v_1, \dots, v_n\}$  refers to the vertices, with weights  $w : V \rightarrow \mathbb{R}$ . Equivalently,  $E \subseteq \{(x, y) | x, y \in V \wedge x \neq y\}$  refers to the edges. When referring to a subnetwork  $S$ ,  $V_S$  is the set of nodes in  $S$  and  $E_S$  is the set of edges in  $S$ . A special case of subgraphs are *connected* subgraphs, which occur when every node in the subgraph can be reached from any other node.

Nodes can be described by properties provided by the topology of the graph. We focused on two of those: degree centrality, and betweenness centrality. The degree centrality, or degree, is the number of edges that a node has. The betweenness centrality, or betweenness, is the number of times a node participates in the shortest paths between two other nodes.

We also used two matrices that describe two different properties of a graph. These matrices are square, and have as many rows and columns as nodes in the network. The element  $(i, j)$  hence represents a relationship between  $v_i$  and  $v_j$ . The *adjacency matrix*  $W_G$  contains a 1 when the corresponding nodes are connected, and 0 otherwise; its diagonal is zero. The *degree matrix*  $D_G$  is a diagonal matrix which contains the degree of the different nodes.

#### 4.3.2 Networks

**Gene network** The mathematical formulations of the different network methods are compatible with any type of biological network (protein interactions, gene coexpression, regulatory, etc.). Here, we used protein-protein interaction networks (PPIN) for all of the network methods except SConES, as PPINs are interpretable, well-characterized, and the methods were designed to run efficiently on them. We built our PPIN from both binary and co-complex interactions stored in the HINT database (release April 2019) [40]. Unless otherwise specified, we used only interactions coming from high-throughput experiments, leaving out targeted studies that might bias the topology of the PPIN. Out of the 146 722 interactions from high-throughput experiments that HINT stores, we were able to map 142 541 to a pair of gene symbols, involving 13 619 genes. 12 880 of those mapped to a genotyped SNP after quality control, involving 127 604 interactions. The scoring function for the nodes changed from method to method (Section 4.3.3).

Additionally, we compared the results obtained on the aforementioned PPIN with those obtained on another PPIN built using interactions coming from both high-throughput and targeted studies. In that case, out of the 179 332 interactions in HINT, 173 797 mapped to a pair of gene symbols. Out of those, 13 735 mapped to a genotyped SNP after quality control, involving 156 190 interactions.

**SNP networks** SConES [16] was the only network method designed to handle SNP networks. As in gene networks, two SNPs were connected in a SNP network when there was evidence of shared functionality between them. Azencott et al. [16] proposed three ways of building these networks: connecting the SNPs consecutive in the genomic sequence (“GS network”); interconnecting all the SNPs mapped to the same gene, on top of GS (“GM network”); and interconnecting all SNPs mapped to two genes for which a protein-protein interaction exists, on top of GM (“GI network”). We focused on

the GI network, as it fitted the scope of this work better, using the PPIN described above. However, at different stages we also compared GI to GS and GM to understand how considering the PPIN affects SConES' output. For the GM network, we used the mapping described in Section 4.3.5. In all three the node scores were the association scores of the individual SNPs with the phenotype (1 d.f.  $\chi^2$  statistic). The properties of these three subnetworks are available in S1 Table.

#### 4.3.3 High-score subnetwork search algorithms

Genes that contribute to the same function are nearby in the PPIN, and can be topologically related to each other in diverse ways (densely interconnected modules, nodes around a hub, a path, etc.). Several aspects have to be taken into consideration when developing a network method: how to score the nodes, whether the affected mechanisms form a single connected component or several, how to frame the problem in a computationally efficient fashion, which network to use, etc. Unsurprisingly, multiple solutions have been proposed. We examined six of them: five that explore the PPIN, and one which explores SNP networks. We selected methods that were open-source, and had an implementation available and accessible documentation. Their main differences are summarized in Table 2. We scored both SNPs and genes with the P-values (or transformations of them) computed in Section 4.2.

**Table 2. Summary of the differences between the network methods.**

Method	Field	Nodes	Exhaustive	Solution	Comp.	Input	Scoring	Ref.
dmGWAS	GWAS	Genes	No	-	1	Summary	$-\log_{10}(P)$	[13]
heinz	Omics	Genes	Yes	-	1	Summary	BUM	[14]
HotNet2	Omics	Genes	Yes	Module	$\geq 1$	Summary	Local FDR	[15]
LEAN	Omics	Genes	Yes	Star	$\geq 1$	Summary	$-\log_{10}(P)$	[12]
SConES	GWAS	SNPs	Yes	Module	$\geq 1$	Genotypes	1 d.f. $\chi^2$	[16]
SigMod	GWAS	Genes	Yes	Module	$\geq 1$	Summary	$\Phi^{-1}(1 - P)$	[17]

**Field:** field in which the algorithm was developed. **Nodes:** the type of nodes in the network, either genes (PPIN) or SNPs. **Exhaustive:** whether all the possible solutions given the selected parameters are explored. **Solution:** additional properties that are enforced on the solution, other than containing high scoring, connected nodes. **Comp.:** number of connected components in the solution. **Input:** genotype data or GWAS summary statistics. **Scoring:** how SNP/gene P-values were transformed into node scores. In the case of heinz, BUM stands for beta-uniform model, used to transform the P-values; for SigMod,  $\Phi^{-1}$  represents the inverse of the cumulative distribution function of the standard Normal distribution. **Ref.:** original publication featuring the algorithm.

**dmGWAS** dmGWAS seeks the subgraph with the highest local density in low P-values [13]. To that end it searches candidate solutions using a greedy, “seed and extend”, heuristic:

1. Select a seed node  $i$  and form the subnetwork  $S_i = \{i\}$ .
2. Compute Stouffer's Z-score  $Z_m$  for  $S_i$  as

$$Z_m = \frac{1}{\sqrt{k}} \sum_{j \in S_i} z_j, \quad (1)$$

where  $k$  is the number of genes in  $S_i$ ;  $z_j$  is the Z score of gene  $j$ , computed as  $\phi^{-1}(1 - P\text{-value}_j)$ ; and  $\phi^{-1}$  is the inverse normal distribution function.

3. Identify neighboring nodes of  $S_i$ , i.e. nodes at distance  $\leq d$ .

- 630     4. Add the neighboring nodes whose inclusion increases  $Z_{m+1}$  by more than a  
       threshold  $Z_m \times (1 + r)$ .  
       631  
       5. Repeat 2-4 until no further enlargement is possible.  
       632  
       6. Add  $S_i$  to the list of subnetworks to return. Normalize its Z-score as  
       633

$$Z_N = \frac{Z_m - \text{mean}(Z_m(\pi))}{\text{SD}(Z_m(\pi))}, \quad (2)$$

634     where  $Z_m(\pi)$  represents a vector containing 100 000 random subsets of the  
       635     same number of genes.

636     DmGWAS carries out this process on every gene in the PPIN. We used the  
       637     implementation of dmGWAS in the dmGWAS 3.0 R package [51]. Unless  
       638     otherwise specified, we used the suggested parameters  $d = 2$  and  $r = 0.1$ . We used  
       639     the function `simpleChoose` to select the solution, which aggregates the top 1%  
       640     subnetworks.

641     **heinz** The goal of heinz is to identify the highest-scored connected subnetwork [14].  
       642     The authors proposed a transformation of the genes' P-value into a score that is  
       643     negative under weak association with the phenotype, and positive under a strong  
       644     one. This transformation is achieved by modeling the distribution of P-values by a  
       645     beta-uniform model (BUM) parameterized by the desired false discovery rate  
       646     (FDR). Thus formulated, the problem is NP-complete, and hence solving it would  
       647     require a prohibitively long computational time. To solve it efficiently it is re-cast  
       648     as the Prize-Collecting Steiner Tree Problem (PCST), which seeks to select the  
       649     connected subnetwork S that maximizes the *profit*  $p(S)$ , defined as:

$$p(S) = \sum_{v \in V_S} p(v) - \sum_{e \in E_S} c(e). \quad (3)$$

650     were  $p(v) = w(v) - w'$  is the *profit* of adding a node,  $c(e) = w'$  is the *cost* of  
       651     adding an edge, and  $w' = \min_{v \in V_G} w(v)$  is the smallest node weight of  $G$ . All  
       652     three are positive quantities. Heinz implements the algorithm from Ljubić et  
       653     al. [52] which, in practice is often fast and optimal, although neither is guaranteed.  
       654     We used BioNet's implementation of heinz [53, 54].

655     **HotNet2** HotNet2 was developed to find connected subgraphs of genes frequently  
       656     mutated in cancer [15]. To that end, it considers both the local topology of the  
       657     PPIN and the scores of the nodes. The former is captured by an insulated heat  
       658     diffusion process: at initialization, the score of the node determines its initial heat;  
       659     iteratively each node yields heat to its "colder" neighbors, and receives heat from  
       660     its "hotter" neighbors while retaining part of its own (hence, *insulated*). This  
       661     process continues until a stationary state is reached, in which the temperature of  
       662     nodes does not change anymore, and results in a diffusion matrix  $F$ .  $F$  is used to  
       663     compute the similarity matrix  $E$  that models exchanged heat as

$$E = F \text{diag}(w(V)), \quad (4)$$

664     where  $\text{diag}(w(V))$  is a diagonal matrix with the node scores in its diagonal. For  
       665     any two nodes  $i$  and  $j$ ,  $E_{ij}$  models the amount of heat that diffuses from node  $j$   
       666     to node  $i$ , which can be interpreted as a (non-symmetric) similarity between those  
       667     two nodes. To obtain densely connected solutions, HotNet2 prunes  $E$ , only

preserving edges such that  $w(E) > \delta$ . Lastly, HotNet2 evaluates the statistical significance of the solutions by comparing their size to the size of PPINs obtained by permuting the node scores. We assigned initial node scores as in Nakka et al. [43], assigning a score of 0 for the genes with a low probability of being associated to the disease, and  $-\log_{10}(\text{P-value})$  to those likely to be. In the GENESIS dataset, the threshold separating both was a P-value of 0.125, which was obtained using a local FDR approach [55]. HotNet2 has two parameters: the restart probability  $\beta$ , and the threshold heat  $\delta$ . Both parameters are set automatically by the algorithm, which is robust to their values [15]. HotNet2 is implemented in Python [56].

**LEAN** LEAN searches altered “star” subnetworks, that is, subnetworks composed by one central node and all its interactors [12]. By imposing this restriction, LEAN can exhaustively test all such subnetworks (one per node). For a particular subnetwork of size  $m$ , the P-values corresponding to the involved nodes are ranked as  $p_1 \leq \dots \leq p_m$ . Then,  $k$  binomial tests are conducted, to compute the probability of having  $k$  out of  $m$  P-values lower or equal to  $p_k$  under the null hypothesis. The minimum of these  $k$  P-values is the score of the subnetwork. This score is transformed into a P-value through an empirical distribution obtained via a subsampling scheme, where gene sets of the same size are selected randomly, and their score computed. Lastly, P-values are corrected for multiple testing through a Benjamini-Hochberg correction. We used the implementation of LEAN from the LEANR R package [57].

**SConES** SConES searches the minimal, modular, and maximally associated subnetwork in a SNP graph [16]. Specifically, it solves the problem

$$\arg \max_{S \subseteq G} \underbrace{\sum_{v \in V_S} w(v)}_{\text{association}} - \lambda \underbrace{\sum_{v \in V_S} \sum_{u \notin V_S} W_{vu}}_{\text{connectivity}} - \underbrace{\eta |V_S|}_{\text{sparsity}} \quad (5)$$

where  $\lambda$  and  $\eta$  are parameters that control the sparsity and the connectivity of the model. The connectivity term penalizes disconnected solutions, with many edges between nodes that are selected and nodes that are not. Given a  $\lambda$  and an  $\eta$ , the aforementioned problem has a unique solution, that SConES finds using a graph min-cut procedure. As in Azencott et al. [16], we selected  $\lambda$  and  $\eta$  by cross-validation, choosing the values that produce the most stable solution across folds. In this case, the selected parameters were  $\eta = 3.51$ ,  $\lambda = 210.29$  for SConES GS;  $\eta = 3.51$ ,  $\lambda = 97.61$  for SConES GM; and  $\eta = 3.51$ ,  $\lambda = 45.31$  for SConES GI. We used the version on SConES implemented in the R package `martini` [58].

**SigMod** SigMod aims at identifying the highest-scoring, most densely connected subnetwork [17]. It addresses an optimization problem similar to that of SConES (Equation 5), but the connectivity term encourages connected solutions by favoring solutions where many edges connect two selected nodes, rather than penalizing disconnected ones:

$$\arg \max_{S \subseteq G} \underbrace{\sum_{v \in V_S} w(v)}_{\text{association}} + \lambda \underbrace{\sum_{v \in V_S} \sum_{u \in V_S} W_{vu}}_{\text{connectivity}} - \underbrace{\eta |V_S|}_{\text{sparsity}} . \quad (6)$$

As for SConES, this optimization problem can also be solved by a graph min-cut approach.

SigMod presents three important differences with SConES. First, it is designed for PPINs. Second, it favors solutions containing many edges. SConES, instead, penalizes connections between the selected and unselected nodes. Third, it explores the grid of parameters differently, and processes their respective solutions. Specifically, for the range of  $\lambda = \lambda_{\min}, \dots, \lambda_{\max}$  for the same  $\eta$ , it prioritizes the solution with the largest change in size from  $\lambda_n$  to  $\lambda_{n+1}$ . Additionally, that change needs to be larger than a user specified threshold `maxjump`. Such a large change implies that the network is densely interconnected. This results in one candidate solution for each  $\eta$ , which are processed by removing any node not connected to any other. A score is assigned to each candidate solution by summing their node scores and normalizing by size. The candidate solution with the highest standardized score and that is not larger than a user-specified threshold (`nmax`) is the chosen solution. We used the default parameters `maxjump` = 10 and `nmax` = 300. SigMod is implemented in an R package [59].

**Consensus** We built a consensus solution by retaining the genes that were selected by at least two of the six methods (using SConES GI for SConES). Any edge between the selected genes in the PPIN was included.

We performed all the computations in the cluster described in Section 4.8.

#### 4.3.4 Parameter space

We used the network methods with the parameters recommended by their authors, or with the default parameters in their absence. Additionally, we explored the parameter space of the different methods to study how they alter the output.

**dmGWAS** We tested multiple values for `r` (0.0001, 0.001, 0.01, 0.05, 0.1, 0.25, 0.5, and 1) and `d` (1, 2, and 3).

**heinz** We tested multiple FDR thresholds (0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1).

**HotNet2** We tested different thresholds to decide which genes would receive a score of 0, and which ones a score of  $-\log_{10}(\text{P-value})$ : 0.001, 0.01, 0.05, 0.125, 0.25, and 0.5.

**LEAN** We used the following significance cutoffs for LEAN's P-values (0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, and 1).

**SConES** We used the values of  $\lambda$  and  $\eta$  that `martini` explores by default (35.54, 5.40, 0.82, 0.12, 0.02, 0.01, 4.39e-4, 6.68e-5, 1.02e-5, and 1.55e-6 in both cases)

**SigMod** We tested multiple values for the parameters `nmax` (10, 50, 100, 300, 700, 1000, and 10 000) and `maxjump` (5, 10, 20, 30, and 50).

#### 4.3.5 Comparing SNP-methods to gene-methods, and vice versa

In multiple steps of this article, we needed to compare the outcome of a method that works on genes with the outcome of another method that works on SNPs. For this purpose, we used the SNP-gene correspondence described in Section 4.2. To convert a list of SNPs into a list of genes, we included all the genes that can be mapped to any of the SNPs. Conversely, to convert a list of genes into a list of SNPs, we included all the SNPs that can be mapped to any of the genes.

## 4.4 Pathway enrichment analysis

We searched for pathways enriched in the gene solutions produced by the above methods. We conducted a hypergeometric test on pathways from Reactome [60] using the function `enrichPathway` from the `ReactomePA` R package [61]. The universe of genes included any gene that we could map to a SNP in the iCOGS array (Section 4.2). We adjusted the P-values for multiple testing as in Benjamini and Hochberg [62] (BH): pathways with a BH adjusted P-value < 0.05 were deemed significant.

## 4.5 Benchmark of methods

We evaluated multiple properties (described in Sections 4.5.1 and 4.5.2) of the different methods through a 5-fold subsampling setting. We applied each method to 5 random subsets of the original GENESIS dataset containing 80% of the samples (*train set*). When pertinent, we evaluated the solution on the remaining 20% (*test set*). We used the 5 repetitions to estimate the average and the standard deviation of the different measures. Every method and repetition ran on the same computational settings (Section 4.8).

### 4.5.1 Properties of the solution

We compared the runtime, the number of selected features (genes or SNPs), and the stability (sensitivity of the result to small changes in the input, here, using different *train* sets) of the different network methods. Nogueira and Brown [63] proposed quantifying the stability of a method using the Pearson correlation between the genes selected on different subsamples. This correlation was calculated between vectors with the length of the total number of features, containing a 0 at position  $i$  if feature  $i$  was not selected, and 1 if it was.

### 4.5.2 Classification accuracy of selected SNPs

A desirable solution offers good predictive power on unseen *test* samples. We evaluated the predicting power of the SNPs selected by the different methods through the performance of an L1-penalized logistic regression classifier, which searches for a small subset of SNPs which provides good classification accuracy. We trained the classifier exclusively on those selected SNPs to predict the outcome (case/control). The L1 penalty helps to account for linkage disequilibrium by reducing the number of SNPs included in the model (*active set*) while improving the generalization of the classifier. This penalty was set by cross-validation, choosing the value that minimized misclassification error. We applied each network method to each train set, and trained the classifier on the same train set using only the selected SNPs. When the method retrieved a list of genes (all of them except SConES), we considered as selected all the SNPs mapped to any of those genes. Then we evaluated the sensitivity and the specificity of the classifier on the test set. The active set gave an estimate of a plausible, more sparse solution with comparable predictive power to the original solution. To obtain a baseline, we also trained the classifier on all the SNPs of the train set. We do not expect a linear model on selected SNPs to be able to separate cases from controls well. Indeed, the lifetime cumulative incidence of breast cancer among women with a family history of breast or ovarian cancer, and no *BRCA1/2* mutations, is only 3.9 times more than in the general population [64]. However, classification accuracy may be one additional informative criterion on which to evaluate solutions.

## 4.6 Comparison to state-of-the-art

An alternative way to evaluate the results is by comparing our results to an external dataset. For that purpose, we used the 153 genes associated to familial breast cancer on DisGeNET [65]. Across this article we refer to these genes as *breast cancer susceptibility genes*.

Additionally, we used the summary statistics from the Breast Cancer Association Consortium (BCAC), a meta-analysis of case-control studies conducted in multiple countries. BCAC included 13 250 641 SNPs genotyped or imputed on 228 951 women of European ancestry mostly from the general population [19]. Through imputation, BCAC includes more SNPs than the iCOGS array used for GENESIS (Section 4.1). Yet, in all the comparisons in this paper, we focused on the subset of the GENESIS SNPs that passed quality control. Hence, we used the same Bonferroni threshold as in Section 4.2 to determine the significant SNPs in BCAC. We also computed gene-scores in the BCAC data using VEGAS2, as in Section 4.1. In this case, we did use the summary statistics of all 13 250 641 available SNPs, and the genotypes from European samples from the 1000 Genomes Project [66] to compute the LD patterns. Since these genotypes did not include chromosome X, we excluded it from this analysis. All comparisons included only the genes common to GENESIS and BCAC, so we used the corresponding Bonferroni threshold ( $1.66 \times 10^{-6}$ ) to call gene significance.

## 4.7 Network rewirings

Rewiring the PPIN while preserving the number of edges of each gene allowed to study the impact of the topology on the output of network methods. Indeed, the edges lose their biological meaning but the topology of the network is conserved. We produced 100 such rewirings by swapping edges in the PPIN. We scored the genes as described in section 4.3.3. We only applied only four methods on the rewirings: heinz, dmGWAS, LEAN and SigMod. We excluded HotNet2 and SConES, since they take notably longer to run than the other methods.

## 4.8 Computational resources

We ran all the computations on a Slurm cluster, running Ubuntu 16.04.2 on the nodes. The CPU models on the nodes were Intel Xeon CPU E5-2450 v2 at 2.50GHz and Intel Xeon E5-2440 at 2.40GHz. The nodes running heinz and HotNet2 had 20GB of memory; the ones running dmGWAS, LEAN, SConES, and SigMod, 60GB. For the benchmark (Section 4.5), we ran each of the methods on the same Ubuntu 16.04.2 node, with a CPU Intel Xeon E5-2450 v2 at 2.50GHz, and 60GB of memory.

## 4.9 Code and data availability

We developed computational pipelines for several steps of GWAS analyses, such as physically mapping SNPs to genes, computing gene scores, and performing six different network analyses. For each of those processes, we created a pipeline with a clear interface that should work on any GWAS dataset. They are compiled in <https://github.com/hclimente/gwas-tools>. The code to apply the pipelines to GENESIS, as well as the code that reproduces all the analyses in this article are available at <https://github.com/hclimente/genewa>. We deposited all the produced gene solutions on NDEX (<http://www.ndexbio.org>), under the UUID e9b0e22a-e9b0-11e9-bb65-0ac135e8bacf.

Summary statistics for SNPs and genes are available at <https://github.com/hclimente/genewa>. We cannot share genotype data publicly

for confidentiality reasons, but are available from GENESIS. Interested researchers can contact nadine.andrieu(at)curie.fr.

## 5 Supporting information

**S1 Table. Summary statistics on the results of SConES on the three SNP-SNP interaction networks.** The first row within each block contains the summary statistics on the whole network.

**S2 Table. Summary statistics on the results of multiple network methods on the PPIN.** The first row contains the summary statistics on the whole PPIN.

**S3 Table. Pathway enrichment analyses of the genes in SigMod solution.**

**S4 Table. Pathway enrichment analyses of the genes in dmGWAS solution.**

**S5 Table. Pathway enrichment analyses of the genes in HotNet2 solution.**

**S6 Table. Pathway enrichment analyses of the genes in the consensus solution.**

**S1 Fig. GENESIS shows no differential population structure between cases and controls. (A,B,C,D)** Eight main principal components computed on the genotypes of GENESIS. Cases are colored in green, controls in orange.

**S2 Fig. Association in GENESIS. The red line represents the Bonferroni threshold. (A)** SNP association, measured from the outcome of a 1 d.f.  $\chi^2$  allelic test (Section 4.2). Significant SNPs that are within a coding gene, or within 50 kilobases of its boundaries, are annotated. The Bonferroni threshold is  $2.54 \times 10^{-7}$ . **(B)** Gene association, measured by P-value of VEGAS2 [42] using the 10% of SNPs with the lowest P-values (Section 4.2). The Bonferroni threshold is  $1.53 \times 10^{-6}$ . **(C)** SNP association as in panel (A). The SNPs in black are selected by a L1-penalized logistic regression (Section 4.5.2,  $\lambda = 0.03$ ).

**S3 Fig. Pearson correlation between the different solutions.**

**(A)** Correlation between selected SNPs. **(B)** Correlation between selected genes. In general, the solutions display a very low overlap.

**S4 Fig. Relationship between the  $\log_{10}$  of the betweenness centrality and the  $-\log_{10}$  of the VEGAS2 P-value of the genes in the consensus solution.** The blue line represents a fitted generalized linear model.

**S5 Fig. Additional benchmarks of the network methods** **(A)** Precision and recall of the evaluated methods with respect to Bonferroni-significant SNPs/genes in BCAC. For reference, we added a gray line with a slope of 1. This panel is identical to Fig 2. **(B)** Sensitivity and specificity on the test set of the L1-penalized logistic regression trained on the features selected by each of the methods. The performance of the classifier trained on all SNPs is also displayed. Points are the average over the 5 runs; the error bars represent the standard error of the mean.

**S6 Fig.** Number of times a gene was selected by either dmGWAS, heinz, LEAN, or SigMod in 100 rewirings of the PPIN (Section 4.7) and its centrality degree. This figure is equivalent to Fig 4B, split by method.

879  
880  
881

**S7 Fig. Parameter space of the network methods.** (A) Size of the solution produced by different parameter values, expressed as a percentage of the maximum solution size for the method, or the highest tested value for the parameter, respectively. The size of the solution is the median among all the solution sizes for the same parameter. (B) Boxplot of the solution sizes of the methods under the explored parameters (Section 4.3.4). (C) Pearson correlation between the solutions of the different runs.

882  
883  
884  
885  
886  
887  
888

**S8 Fig. Biotypes of genes from the annotation that are not present in the HINT PPIN.**

889  
890

**S9 Fig. Comparison of the benchmark on high-throughput (HT) interactions to the benchmark on both high-throughput and literature curated interactions (HT+LC).** Grey lines represent no change in the statistic between the benchmarks (1 for ratios mean(HT) / mean(HT + LC), 0 for differences mean(HT) - mean(HT + LC)). (A) Ratios of the selected features between both benchmarks and of the active set (Section 4.5.2). (B) Shifts in sensitivity and specificity. (C) Shift in Pearson correlation between benchmarks. (D) Ratio between the runtimes of the benchmarks. For gene-based methods, inverted triangles represent the ratio of runtimes of the algorithms themselves, and circles the total time, which includes the algorithm themselves and the additional 119 980 seconds (1 day and 9.33 hours) that VEGAS2 took on average to compute the gene scores from SNP summary statistics. In general, adding additional interactions slightly improves the stability of the solution, but increases the solution size, has mixed effects on the sensitivity and specificity, and impacts negatively the required runtime of the algorithms.

891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904

**S10 Fig. Overview of the solutions produced by the SConES on the GS and GM networks (Section 4.3.2) on the GENESIS dataset.** (A) Manhattan plots of SNPs (Section 4.2); in black, the method's solution. The Bonferroni threshold ( $2.54 \times 10^{-7}$ ) is indicated by a red line. (B) Precision and recall of the evaluated methods with respect to Bonferroni-significant SNPs (SConES) or genes (other methods) in BCAC. For reference, we added a gray line with a slope of 1. (C) Solution networks.

905  
906  
907  
908  
909  
910

## Acknowledgments

911

We wish to thank Om Kulkarni for helpful discussion on gene-based GWAS and PPIN databases, and the genetic epidemiology platform (the PIGE, Plateforme d'Investigation en Génétique et Epidemiologie: S. Eon-Marchais, M. Marcou, D. Le Gal, L. Toulemonde, J. Beauvallet, N. Mebirouk, E. Cavaciuti), the biological resource centre (S. Mazoyer, F. Damiola, L. Barjhoux, C. Verny-Pierre, V. Sornin). We wish to pay a tribute to Olga M. Sinilnikova, who was one of the initiators and principal investigators of GENESIS and who died prematurely on June 30, 2014.

912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923

We thank all the GENESIS collaborating cancer clinics clinics (Clinique Sainte Catherine, Avignon: H. Dreyfus; Hôpital Saint Jacques, Besançon: M-A. Collonge-Rame; Institut Bergonié, Bordeaux: M. Longy, A. Floquet, E. Barouk-Simonet; CHU, Brest: S. Audebert; Centre François Baclesse, Caen: P. Berthet; Hôpital Dieu, Chambéry: S. Fert-Ferrer; Centre Jean Perrin, Clermont-Ferrand: Y-J. Bignon; Hôpital

Pasteur, Colmar: J-M. Limacher; Hôpital d'Enfants CHU – Centre Georges François Leclerc, Dijon: L. Faivre-Olivier; CHU, Fort de France: O. Bera; CHU Albert Michallon, Grenoble: D. Leroux; Hôpital Flaubert, Le Havre: V. Layet; Centre Oscar Lambret, Lille: P. Vennin, C. Adenis; Hôpital Jeanne de Flandre, Lille: S. Lejeune-Dumoulin, S. Manouvier-Hanu; CHRU Dupuytren, Limoges: L. Venat-Bouvet; Centre Léon Bérard, Lyon: C. Lasset, V. Bonadona; Hôpital Edouard Herriot, Lyon: S. Giraud; Institut Paoli-Calmettes, Marseille: F. Eisinger, L. Huiart; Centre Val d'Aurelle – Paul Lamarque, Montpellier: I. Coupier; CHU Arnaud de Villeneuve, Montpellier: I. Coupier, P. Pujol; Centre René Gauducheau, Nantes: C. Delnatte; Centre Catherine de Sienne, Nantes: A. Lortholary; Centre Antoine Lacassagne, Nice: M. Frénay, V. Mari; Hôpital Caremeau, Nîmes: J. Chiesa; Réseau Oncogénétique Poitou Charente, Niort: P. Gesta; Institut Curie, Paris: D. Stoppa-Lyonnet, M. Gauthier-Villars, B. Buecher, A. de Pauw, C. Abadie, M. Belotti; Hôpital Saint-Louis, Paris: O. Cohen-Haguenauer; Centre Viggo-Petersen, Paris: F. Cornélis; Hôpital Tenon, Paris: A. Fajac; GH Pitié Salpêtrière et Hôpital Beaujon, Paris: C. Colas, F. Soubrier, P. Hammel, A. Fajac; Institut Jean Godinot, Reims: C. Penet, T. D. Nguyen; Polyclinique Courlancy, Reims: L. Demange*, C. Penet; Centre Eugène Marquis, Rennes: C. Dugast*; Centre Henri Becquerel, Rouen: A. Chevrier, T. Frebourg, J. Tinat, I. Tennevret, A. Rossi; Hôpital René Huguemin/Institut Curie, Saint Cloud: C. Noguès, L. Demange*, E. Mouret-Fourme; CHU, Saint-Etienne: F. Prieur; Centre Paul Strauss, Strasbourg: J-P. Fricker, H. Schuster; Hôpital Civil, Strasbourg: O. Caron, C. Maugard; Institut Claudius Regaud, Toulouse: L. Gladieff, V. Feille; Hôpital Bretonneau, Tours: I. Mortemousque; Centre Alexis Vautrin, Vandoeuvre-les-Nancy: E. Luporsi; Hôpital de Bravois, Vandoeuvre-les-Nancy: P. Jonveaux; Gustave Roussy, Villejuif: A. Chompret*, O. Caron). *Deceased prematurely	924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948
--	---

## Author contributions

<b>Conceptualization</b> Héctor Climente-González, Christine Lonjou, Chloé-Agathe Azencott.	950 951
<b>Data curation</b> Christine Lonjou, GENESIS Study collaborators.	952
<b>Formal Analysis</b> Héctor Climente-González, Christine Lonjou.	953
<b>Funding acquisition</b> Dominique Stoppa-Lyonnet, Nadine Andrieu, Chloé-Agathe Azencott.	954 955
<b>Investigation</b> Héctor Climente-González, Christine Lonjou.	956
<b>Methodology</b> Héctor Climente-González, Christine Lonjou, Chloé-Agathe Azencott.	957
<b>Project administration</b> Chloé-Agathe Azencott.	958
<b>Resources</b> GENESIS Study collaborators, Dominique Stoppa-Lyonnet, Nadine Andrieu.	959 960
<b>Software</b> Héctor Climente-González, Christine Lonjou.	961
<b>Supervision</b> Christine Lonjou, Fabienne Lesueur, Nadine Andrieu, Chloé-Agathe Azencott.	962 963
<b>Validation</b> Christine Lonjou, Fabienne Lesueur.	964
<b>Visualization</b> Héctor Climente-González.	965

<b>Writing – original draft</b>	Héctor Climente-González.	966
<b>Writing – review &amp; editing</b>	Héctor Climente-González, Christine Lonjou, Fabienne Lesueur, Nadine Andrieu, Chloé-Agathe Azencott.	967
		968

## References

1. Bush WS, Moore JH. Chapter 11: Genome-Wide Association Studies. PLoS Computational Biology. 2012;8(12):e1002822. doi:10.1371/journal.pcbi.1002822.
2. Buniello A, MacArthur JA, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Research. 2019;47(D1):D1005–D1012. doi:10.1093/nar/gky1120.
3. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. The American Journal of Human Genetics. 2017;101(1):5–22. doi:10.1016/j.ajhg.2017.06.005.
4. Wang MH, Cordell HJ, Van Steen K. Statistical methods for genome-wide association studies. Seminars in Cancer Biology. 2018;doi:10.1016/j.semcan.2018.04.008.
5. Barton NH, Etheridge AM, Véber A. The infinitesimal model: Definition, derivation, and implications. Theoretical Population Biology. 2017;118:50–73. doi:10.1016/j.tpb.2017.06.001.
6. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to Omnipgenic. Cell. 2017;169(7):1177–1186. doi:10.1016/j.cell.2017.05.038.
7. Furlong LI. Human diseases through the lens of network biology. Trends in Genetics. 2013;29(3):150–159. doi:10.1016/j.tig.2012.11.004.
8. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nature Reviews Genetics. 2011;12(1):56–68. doi:10.1038/nrg2918.
9. Cai JJ, Borenstein E, Petrov DA. Broker Genes in Human Disease. Genome Biology and Evolution. 2010;2:815–825. doi:10.1093/gbe/evq064.
10. Huang JK, Carlin DE, Yu MK, Zhang W, Kreisberg JF, Tamayo P, et al. Systematic Evaluation of Molecular Networks for Discovery of Disease Genes. Cell Systems. 2018;6(4):484–495.e5. doi:10.1016/j.cels.2018.03.001.
11. Azencott CA. Network-Guided Biomarker Discovery. In: Machine Learning for Health Informatics. vol. 9605. Cham: Springer International Publishing; 2016. p. 319–336. Available from: [http://link.springer.com/10.1007/978-3-319-50478-0\\_16](http://link.springer.com/10.1007/978-3-319-50478-0_16).
12. Gwinner F, Boulday G, Vandiedonck C, Arnould M, Cardoso C, Nikolayeva I, et al. Network-based analysis of omics data: The LEAN method. Bioinformatics. 2016; p. btw676. doi:10.1093/bioinformatics/btw676.
13. Jia P, Zheng S, Long J, Zheng W, Zhao Z. dmGWAS: dense module searching for genome-wide association studies in protein–protein interaction networks. Bioinformatics. 2011;27(1):95–102. doi:10.1093/bioinformatics/btq615.

14. Dittrich MT, Klau GW, Rosenwald A, Dandekar T, Muller T. Identifying functional modules in protein-protein interaction networks: an integrated exact approach. *Bioinformatics*. 2008;24(13):i223–i231. doi:10.1093/bioinformatics/btn161.
15. Leiserson MDM, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. *Nature Genetics*. 2015;47(2):106–114. doi:10.1038/ng.3168.
16. Azencott CA, Grimm D, Sugiyama M, Kawahara Y, Borgwardt KM. Efficient network-guided multi-locus association mapping with graph cuts. *Bioinformatics*. 2013;29(13):i171–i179. doi:10.1093/bioinformatics/btt238.
17. Liu Y, Brossard M, Roqueiro D, Margaritte-Jeannin P, Sarnowski C, Bouzignon E, et al. SigMod: an exact and efficient method to identify a strongly interconnected disease-associated module in a gene network. *Bioinformatics*. 2017; p. btx004. doi:10.1093/bioinformatics/btx004.
18. Sinilnikova OM, Dondon MG, Eon-Marchais S, Damiola F, Barjhoux L, Marcou M, et al. GENESIS: a French national resource to study the missing heritability of breast cancer. *BMC Cancer*. 2016;16(1):13. doi:10.1186/s12885-015-2028-9.
19. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature*. 2017;551(7678):92–94. doi:10.1038/nature24284.
20. Mulligan AM, , Couch FJ, Barrowdale D, Domchek SM, Eccles D, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*. 2011;13(6). doi:10.1186/bcr3052.
21. Rinella ES, Shao Y, Yackowski L, Pramanik S, Oratz R, Schnabel F, et al. Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. *Human Genetics*. 2013;132(5):523–536. doi:10.1007/s00439-013-1269-4.
22. Brisbin AG, Asmann YW, Song H, Tsai YY, Aakre JA, Yang P, et al. Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. *BMC Medical Genetics*. 2011;12(1):156. doi:10.1186/1471-2350-12-156.
23. SEARCH, The GENICA Consortium, kConFab, Australian Ovarian Cancer Study Group, Ahmed S, Thomas G, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature Genetics*. 2009;41(5):585–590. doi:10.1038/ng.354.
24. Nielsen FC, van Overeem Hansen T, Sørensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. *Nature Reviews Cancer*. 2016;16(9):599–612. doi:10.1038/nrc.2016.72.
25. Piñero J, Berenstein A, Gonzalez-Perez A, Chernomoretz A, Furlong LI. Uncovering disease mechanisms through network biology in the era of Next Generation Sequencing. *Scientific Reports*. 2016;6(1):24570. doi:10.1038/srep24570.

26. Quigley DA, Fiorito E, Nord S, Van Loo P, Alnaes GG, Fleischer T, et al. The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors. *Molecular Oncology*. 2014;8(2):273–284. doi:10.1016/j.molonc.2013.11.008.
27. Yu M, Li R, Zhang J. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer. *Biochemical and Biophysical Research Communications*. 2016;471(4):639–645. doi:10.1016/j.bbrc.2016.02.072.
28. Liu G, Claret FX, Zhou F, Pan Y. Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer. *Frontiers in Pharmacology*. 2018;9:135. doi:10.3389/fphar.2018.00135.
29. de los Campos G, Vazquez AI, Hsu S, Lello L. Complex-Trait Prediction in the Era of Big Data. *Trends in Genetics*. 2018;34(10):746–754. doi:10.1016/j.tig.2018.07.004.
30. Nikolayeva I, Guitart Pla O, Schwikowski B. Network module identification—A widespread theoretical bias and best practices. *Methods*. 2018;132:19–25. doi:10.1016/j.ymeth.2017.08.008.
31. Ioachim E, Charchanti A, Briassoulis E, Karavasilis V, Tsanou H, Arvanitis DL, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. *European Journal of Cancer*. 2002;38(18):2362–2370. doi:10.1016/s0959-8049(02)00210-1.
32. Yi W, Xiao E, Ding R, Luo P, Yang Y. High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF- $\kappa$ B/p53-apoptosis signaling pathway in colorectal cancer. *Oncology Reports*. 2016;36(6):3145–3153. doi:10.3892/or.2016.5177.
33. Sponzillo M, Rosignolo F, Celano M, Maggisano V, Pecce V, Rose RFD, et al. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. *Molecular and Cellular Endocrinology*. 2016;431:123–132. doi:10.1016/j.mce.2016.05.007.
34. Ahmed S, Thomas G, Ghousaini M, Healey CS, Humphreys MK, Platte R, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature Genetics*. 2009;41(5):585–590. doi:10.1038/ng.354.
35. Breyer J, Dorset D, Clark T, Bradley K, Wahlfors T, McReynolds K, et al. An Expressed Retrogene of the Master Embryonic Stem Cell Gene POU5F1 Is Associated with Prostate Cancer Susceptibility. *The American Journal of Human Genetics*. 2014;94(3):395–404. doi:10.1016/j.ajhg.2014.01.019.
36. Chen HY, Chen RH. Cullin 3 Ubiquitin Ligases in Cancer Biology: Functions and Therapeutic Implications. *Frontiers in Oncology*. 2016;6. doi:10.3389/fonc.2016.00113.
37. Loignon M, Miao W, Hu L, Bier A, Bismar TA, Scrivens PJ, et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. *Molecular Cancer Therapeutics*. 2009;8(8):2432–2440. doi:10.1158/1535-7163.mct-08-1186.
38. Halsey LG, Curran-Everett D, Vowler SL, Drummond GB. The fickle P value generates irreproducible results. *Nature Methods*. 2015;12(3):179–185. doi:10.1038/nmeth.3288.

39. Wagner A, Wright J. Alternative routes and mutational robustness in complex regulatory networks. *Biosystems*. 2007;88(1-2):163–172. doi:10.1016/j.biosystems.2006.06.002.
40. Das J, Yu H. HINT: High-quality protein interactomes and their applications in understanding human disease. *BMC Systems Biology*. 2012;6(1):92. doi:10.1186/1752-0509-6-92.
41. Gallagher MD, Chen-Plotkin AS. The Post-GWAS Era: From Association to Function. *The American Journal of Human Genetics*. 2018;102(5):717–730. doi:10.1016/j.ajhg.2018.04.002.
42. Mishra A, Macgregor S. VEGAS2: Software for More Flexible Gene-Based Testing. *Twin Research and Human Genetics*. 2015;18(1):86–91. doi:10.1017/thg.2014.79.
43. Nakka P, Raphael BJ, Ramachandran S. Gene and Network Analysis of Common Variants Reveals Novel Associations in Multiple Complex Diseases. *Genetics*. 2016;204(2):783–798. doi:10.1534/genetics.116.188391.
44. Ionita-Laza I, Lee S, Makarov V, Buxbaum J, Lin X. Sequence Kernel Association Tests for the Combined Effect of Rare and Common Variants. *The American Journal of Human Genetics*. 2013;92(6):841–853. doi:10.1016/j.ajhg.2013.04.015.
45. Wang M, Huang J, Liu Y, Ma L, Potash JB, Han S. COMBAT: A Combined Association Test for Genes Using Summary Statistics. *Genetics*. 2017;207(3):883–891. doi:10.1534/genetics.117.300257.
46. Xie T. Analysis of the Gene-Dense Major Histocompatibility Complex Class III Region and Its Comparison to Mouse. *Genome Research*. 2003;13(12):2621–2636. doi:10.1101/gr.1736803.
47. Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. *Nature Biotechnology*. 2017;35(4):316–319. doi:10.1038/nbt.3820.
48. Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward findings for hormonally mediated cancers. *Nature Genetics*. 2013;45(4):345–348. doi:10.1038/ng.2587.
49. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience*. 2015;4(1):7. doi:10.1186/s13742-015-0047-8.
50. Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Research*. 2019;47(D1):D766–D773. doi:10.1093/nar/gky955.
51. Wang Q, Jia P. dmGWAS 3.0; 2014. <https://bioinfo.uth.edu/dmGWAS/>.
52. Ljubić I, Weiskircher R, Pferschy U, Klau GW, Mutzel P, Fischetti M. An Algorithmic Framework for the Exact Solution of the Prize-Collecting Steiner Tree Problem. *Mathematical Programming*. 2006;105(2-3):427–449. doi:10.1007/s10107-005-0660-x.

53. Beisser D, Klau GW, Dandekar T, Muller T, Dittrich MT. BioNet: an R-Package for the functional analysis of biological networks. *Bioinformatics*. 2010;26(8):1129–1130. doi:10.1093/bioinformatics/btq089.
54. Dittrich M, Beisser D. BioNet; 2008. <https://bioconductor.org/packages/BioNet/>.
55. Scheid S, Spang R. twilight; a Bioconductor package for estimating the local false discovery rate. *Bioinformatics*. 2005;21(12):2921–2922. doi:10.1093/bioinformatics/bti436.
56. Leiserson MDM, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL, et al.. HotNet2; 2018. <https://github.com/raphael-group/hotnet2>.
57. Gwinner F. LEANR; 2016. <https://cran.r-project.org/web/packages/LEANR/>.
58. Clemente-González H, Azencott CA. martini; 2019. <https://www.bioconductor.org/packages/martini/>.
59. Liu Y. SigMod v2; 2018. <https://github.com/YuanlongLiu/SigMod>.
60. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway knowledgebase. *Nucleic Acids Research*. 2019;doi:10.1093/nar/gkz1031.
61. Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. *Molecular BioSystems*. 2016;12(2):477–479. doi:10.1039/c5mb00663e.
62. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)*. 1995;57(1):289–300. doi:10.1111/j.2517-6161.1995.tb02031.x.
63. Nogueira S, Brown G. Measuring the Stability of Feature Selection. In: Machine Learning and Knowledge Discovery in Databases. vol. 9852. Cham: Springer International Publishing; 2016. p. 442–457. Available from: [http://link.springer.com/10.1007/978-3-319-46227-1\\_28](http://link.springer.com/10.1007/978-3-319-46227-1_28).
64. Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. *British Journal of Cancer*. 2008;100(2):421–425. doi:10.1038/sj.bjc.6604830.
65. Piñero J, Bravo A, Queralt-Rosinach N, Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic Acids Research*. 2017;45(D1):D833–D839. doi:10.1093/nar/gkw943.
66. The 1000 Genomes Project Consortium, Gibbs RA, Boerwinkle E, Doddapaneni H, Han Y, Korchina V, et al. A global reference for human genetic variation. *Nature*. 2015;526(7571):68–74. doi:10.1038/nature15393.